Wright J, White J
Bradford Royal Infirmary, Duckworth Lane, Bradford, W.Yorkshire, UK, BD9 6RJ.
Cochrane Database Syst Rev. 2000(2):CD001106. doi: 10.1002/14651858.CD001106.
Obstructive sleep apnoea (OSA) is the periodic reduction (hypopnoea) or cessation (apnoea) of breathing due to narrowing or occlusion of the upper airway during sleep. The mainstay of nocturnal treatment is continuous positive airway pressure (CPAP) therapy at home at night to prevent the resulting apnoea, hypoxia and sleep fragmentation which are believed to cause the symptoms of OSA. A number of clinical trials have evaluated the effectiveness of nasal CPAP) as a treatment.
The objective was to review the effects of CPAP in the treatment of obstructive sleep apnoea in adults.
We searched Medline 1966 to 1996, Embase 1974 to 1996, Cinahl 1982 to 1995 and the reference lists of articles. We consulted experts in the field.
Randomised trials comparing nocturnal CPAP with placebo or other treatments in adults with obstructive sleep apnoea and an apnoea/hypopnoea index greater than five per hour.
Trial quality was assessed and data were extracted independently by two reviewers. Study authors were contacted for missing information.
Seven trials involving 177 people were included. All the studies had some methodological shortcomings. Six trials were of crossover design. Compared with placebo, CPAP showed significant improvements in several quality of life and depression measures. Patients preferred CPAP to placebo (odds ratio 0.4, 95% confidence interval 0.2 to 0.8). There was no significant effect on blood pressure or measures of sleepiness and sleep quality. Compared with oral appliances, CPAP significantly improved the apnoea/hypopnoea index (weighted mean difference -7.3, 95% confidence interval -10.0 to -4.7) and minimum oxygen saturation during sleep. Patients strongly preferred the oral appliance to CPAP (odds ratio 9.5, 95% confidence interval 4.3 to 21.1).
REVIEWER'S CONCLUSIONS: CPAP appears to be more effective than placebo in improving some quality of life measures for people with obstructive sleep apnoea. It appears to be more effective than oral appliances in improving respiratory disturbances. People appear to prefer oral appliances over CPAP, but prefer CPAP over placebo.
阻塞性睡眠呼吸暂停(OSA)是指睡眠期间由于上呼吸道变窄或阻塞导致的呼吸周期性减少(呼吸浅慢)或停止(呼吸暂停)。夜间治疗的主要方法是在家中进行持续气道正压通气(CPAP)治疗,以预防由此产生的呼吸暂停、缺氧和睡眠片段化,这些被认为会导致OSA的症状。多项临床试验评估了鼻CPAP作为一种治疗方法的有效性。
目的是综述CPAP治疗成人阻塞性睡眠呼吸暂停的效果。
我们检索了1966年至1996年的Medline、1974年至1996年的Embase、1982年至1995年的Cinahl以及文章的参考文献列表。我们咨询了该领域的专家。
将夜间CPAP与安慰剂或其他治疗方法进行比较的随机试验,受试对象为阻塞性睡眠呼吸暂停且呼吸暂停/呼吸浅慢指数每小时大于5次的成年人。
评估试验质量,由两名评价者独立提取数据。联系研究作者获取缺失信息。
纳入了7项涉及177人的试验。所有研究都存在一些方法学上的缺陷。6项试验为交叉设计。与安慰剂相比,CPAP在多项生活质量和抑郁指标上有显著改善。患者更喜欢CPAP而非安慰剂(比值比0.4,95%置信区间0.2至0.8)。对血压或嗜睡及睡眠质量指标无显著影响。与口腔矫治器相比,CPAP显著改善了呼吸暂停/呼吸浅慢指数(加权平均差-7.3,95%置信区间-10.0至-4.7)以及睡眠期间的最低血氧饱和度。患者强烈更喜欢口腔矫治器而非CPAP(比值比9.5,95%置信区间4.3至21.1)。
对于阻塞性睡眠呼吸暂停患者,CPAP在改善某些生活质量指标方面似乎比安慰剂更有效。在改善呼吸紊乱方面,它似乎比口腔矫治器更有效。人们似乎更喜欢口腔矫治器而非CPAP,但更喜欢CPAP而非安慰剂。